Bristol-Myers Squibb(US:BMY) Businesswireยท2025-11-18 03:33Core Points - Bristol Myers Squibb announced early participation results for its tender offers to purchase outstanding notes, with changes to the maximum aggregate purchase prices for both Pool 1 and Pool 2 Notes [1][9] - The company has decreased the maximum purchase price for Pool 1 Notes from $4 billion to an amount sufficient to accept all validly tendered notes, while increasing the maximum for Pool 2 Notes from $3 billion to accommodate all validly tendered notes with priority levels 1 through 4, plus up to $250 million of 5.900% Notes due 2033 [1][8] - The early settlement date for the offers is set for November 20, 2025, with the offers expiring on December 3, 2025, unless extended [9][10] Pool 1 Notes Summary - The total principal amount of Pool 1 Notes validly tendered by the early tender deadline includes $360 million of 4.950% Notes due 2026, $529.9 million of 3.200% Notes due 2026, $519.5 million of 4.900% Notes due 2027, and $560.1 million of 4.900% Notes due 2028 [5][8] - Bristol Myers Squibb does not anticipate accepting any additional tenders of Pool 1 Notes after the early tender deadline due to the maximum purchase price being met [8] Pool 2 Notes Summary - The total principal amount of Pool 2 Notes validly tendered includes $6.2 million of 6.875% Debenture due 2097, $879.2 million of 6.400% Notes due 2063, $811.5 million of 6.250% Notes due 2053, and $1.3 billion of 5.650% Notes due 2064 [7][8] - No Pool 2 Notes with acceptance priority levels 6 through 9 will be accepted for purchase [8] Additional Information - All accepted notes will be cancelled and retired, ceasing to be outstanding obligations of Bristol Myers Squibb [11] - Holders of accepted notes will receive cash payments for accrued and unpaid interest in addition to their total consideration [10]